

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM408159

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
ASPEN PARK PHARMACEUTICALS, INC.		11/28/2016	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	BMO HARRIS BANK N.A.		
Street Address:	111 West Monroe Street		
City:	Chicago		
State/Country:	ILLINOIS		
Postal Code:	60603		
Entity Type:	National Banking Association: ILLINOIS		
PROPERTY NUMBERS Total: 6			
Property Type	Number	Word Mark	
Serial Number:	87034974	VERU HEALTHCARE	
Serial Number:	87004751	VERU BIOPHARMA	
Serial Number:	87004718	VERU PHARMACEUTICALS	
Serial Number:	87004711	VERU PHARMA	
Serial Number:	87004753	VERU	
Serial Number:	86165306	PREBOOST	
CORRESPONDENCE DATA			
Fax Number:			
	<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	248 645-1483		
Email:	ipdocket@h2law.com		
Correspondent Name:	Jacob P. Woolbright		
Address Line 1:	450 West Fourth Street		
Address Line 4:	Royal Oak, MICHIGAN 48067		
NAME OF SUBMITTER:	Jacob P. Woolbright		
SIGNATURE:	/Jacob P. Woolbright/		
DATE SIGNED:	12/08/2016		

CH \$165.00 87034974

Total Attachments: 8

source=Executed Intellectual Property Security Agreement#page1.tif

source=Executed Intellectual Property Security Agreement#page2.tif

source=Executed Intellectual Property Security Agreement#page3.tif

source=Executed Intellectual Property Security Agreement#page4.tif

source=Executed Intellectual Property Security Agreement#page5.tif

source=Executed Intellectual Property Security Agreement#page6.tif

source=Executed Intellectual Property Security Agreement#page7.tif

source=Executed Intellectual Property Security Agreement#page8.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement ("IP Security Agreement"), dated as of November 28, 2016, is made by and among ASPEN PARK PHARMACEUTICALS, INC., a Delaware corporation (the "Grantor") in favor of BMO Harris Bank N.A., a national banking association with its mailing address at 111 West Monroe Street, Chicago, Illinois 60603 (the "Secured Party").

WHEREAS, the Grantor and other Borrower, as borrowers, and Secured Party, as lender, have entered into that certain Credit Agreement dated as of December 29, 2015, as amended by that certain First Amendment and Waiver to Credit Agreement and Security Agreement dated as of January 4, 2016, that certain Consent and Amendment to Credit Agreement dated as of March 31, 2016, and that certain Third Amendment to Credit Agreement dated as of the date hereof by and between Borrowers and Secured Party (collectively, the "Credit Agreement").

WHEREAS, as a condition to the financial accommodations extended to Grantor by the Secured Party under the Credit Agreement, Grantor has executed and delivered to the Secured Party that certain General Security Agreement bearing even date herewith made by and among the Grantor and the Secured Party (the "Security Agreement").

WHEREAS, under the terms of the Security Agreement, the Grantor has granted to the Secured Party a security interest in, among other property, certain intellectual property of the Grantor, and have agreed to execute and deliver this IP Security Agreement, for recording with international, national, federal and state government authorities, including, but not limited to, the United States Patent and Trademark Office and the United States Copyright Office.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantor agrees with the Secured Party as follows:

1. Grant of Security. Grantor hereby pledges and grants to the Secured Party a security interest in and to all of the right, title and interest of Grantor in, to and under the following (the "IP Collateral"):

(a) the patents and patent applications set forth in Schedule 1 hereto and all reissues, divisions, continuations, continuations-in-part, renewals, extensions and reexaminations thereof and amendments thereto (the "Patents");

(b) the trademark registrations and applications set forth in Schedule 2 hereto, together with the goodwill connected with the use thereof and symbolized thereby and all extensions and renewals thereof (the "Trademarks"), excluding only United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant, attachment or enforcement of a security interest therein would, under

applicable federal law, impair the registrability of such applications or the validity or enforceability of registrations issuing from such applications;

(c) all rights of any kind whatsoever of Grantor accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions and otherwise throughout the world;

(d) any and all royalties, fees, income, payments and other proceeds now or hereafter due or payable with respect to any and all of the foregoing; and

(e) any and all claims and causes of action with respect to any of the foregoing, whether occurring before, on or after the date hereof, including all rights to and claims for damages, restitution and injunctive and other legal and equitable relief for past, present and future infringement, dilution, misappropriation, violation, misuse, breach or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this IP Security Agreement upon request by the Secured Party.

3. Loan Documents. This IP Security Agreement has been entered into pursuant to and in conjunction with the Security Agreement, which is hereby incorporated by reference. The provisions of the Security Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of the Secured Party with respect to the IP Collateral are as provided by the Credit Agreement, the Security Agreement and related documents, and nothing in this IP Security Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This IP Security Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this IP Security Agreement by facsimile or in electronic (i.e., "pdf" or "tif") format shall be effective as delivery of a manually executed counterpart of this IP Security Agreement.

5. Successors and Assigns. This IP Security Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

6. Governing Law. This IP Security Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this IP Security Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United

States and the State of Illinois, without giving effect to any choice or conflict of law provision or rule (whether of the State of Illinois or any other jurisdiction).

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Grantor has caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized in Chicago, Illinois as of the date first above written.

GRANTOR:

**ASPEN PARK PHARMACEUTICALS,
INC.**

By: 

Name: Mitchell S. Steiner, M.D.

Title: President and Chief Executive
Officer

Address for Notices:

Aspen Park Pharmaceuticals, Inc.

4400 Biscayne Blvd.

Suite 888

Miami, FL 33137

Attn: Daniel Haines, Chief Financial Officer
and Chief Operating Officer

Phone: 312-595-9123

Facsimile: 312-595-9122

Email: DHaines@veruhealthcare.com

AGREED TO AND ACCEPTED:

BMO HARRIS BANK N.A.,

as Secured Party

By: _____

Name: Jaime Freeman

Title: Vice President

Address for Notices:

BMO Harris Bank N.A.

111 West Monroe Street, SW

Chicago, Illinois 60603

Attn: Jaime Freeman

Phone: 312-461-5147

Facsimile: 312-461-1507

Email: Jaime.Freeman@bmo.com

TRADEMARK

REEL: 005945 FRAME: 0860

IN WITNESS WHEREOF, Grantor has caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized in Chicago, Illinois as of the date first above written.

GRANTOR:

ASPEN PARK PHARMACEUTICALS,
INC.

By: _____

Name: Mitchell S. Steiner, M.D.

Title: President and Chief Executive
Officer

Address for Notices:

Aspen Park Pharmaceuticals, Inc.

4400 Biscayne Blvd.

Suite 888

Miami, FL 33137

Attn: Daniel Haines, Chief Financial Officer
and Chief Operating Officer

Phone: 312-595-9123

Facsimile: 312-595-9122

Email: DHaines@venetiahealthcare.com

AGREED TO AND ACCEPTED:

BMO HARRIS BANK N.A.,

as Secured Party

By: _____

Name: Jaime Freeman

Title: Vice President

Address for Notices:

BMO Harris Bank N.A.

111 West Monroe Street, 5W

Chicago, Illinois 60603

Attn: Jaime Freeman

Phone: 312-461-5147

Facsimile: 312-461-1507

Email: Jaime.Freeman@bmo.com

TRADEMARK

REEL: 005945 FRAME: 0861

SCHEDULE 1

PATENTS AND PATENT APPLICATIONS

ASPEN PARK PHARMACEUTICALS, INC.
Patents

Country	Application No.	Patent No.	Filing Date	Issue Date		
U.S. (Provisional)	60/207,496		26-May-00			
International	PCT/US01/15900		15-May-01			
International (CIP)	PCT/US02/037841		25-Nov-02			
Australia	2001261684	2001261684	21-Nov-02	28-Apr-06		
Brazil	P10111141.8		25-Nov-02			
Canada	2409647	2,409,647	15-May-01	3-Jul-12		
Europe	1935605.4		21-May-01			
Japan	2001-587759		26-Nov-02			
U.S.	09/980,652	6,391,920	26-Oct-01	21-May-02		
U.S. (CIP)	10/081,098	7,067,557	21-Feb-02	27-Jun-06		
U.S. (1st Reexam)	90/006,921	Reexam Certificate 5338	26-Jan-04	11-Apr-06		
U.S. (2nd Reexam)	90/008,024	Reexam Certificate 9617	1-May-06	29-Apr-13		
U.S. (Provisional)	62/028,540		24-Jul-14			
International	PCT/US15/41761		23-Jul-15			
U.S. (Provisional)	61/932,470		28-Jan-14			
International	PCT/US15/11961		20-Jan-15			
U.S.	15/114,620		07-Jul-16			

ASPEN PARK PHARMACEUTICALS, INC.
Patents

Country	Application No.	Patent No.	Filing Date	Issue Date		
U.S. (Provisional)	62/118,773		20-Feb-15			
U.S. (Provisional)	62/299,686		25-Feb-16			
U.S. (Provisional)	62/155052		30-Apr-15			
U.S. (Provisional)	62/331599		4-May-16			

SCHEDULE 2
 TRADEMARK REGISTRATIONS AND APPLICATIONS

ASPEN PARK PHARMACEUTICALS, INC. Trademarks						
Country	Trademark	Application No.	Filing Date	Registration No.	Registration Date	Status
U.S.	VERU HEALTHCARE	87034974	12-May-16			Pending
U.S.	VERU BIOPHARMA	87004751	18-Apr-16			Pending
U.S.	VERU PHARMACEUTICALS	87004718	18-Apr-16			Pending
U.S.	VERU PHARMA	87004711	18-Apr-16			Pending
U.S.	VERU	87004753	18-Apr-16			Pending
U.S.	PREBOOST	86165306	14-Jan-14	4668640	6-Jan-15	Current

4839-8710-2012